Eidelman Virant Capital cut its position in AbbVie Inc. (NYSE:ABBV – Get Rating) by 1.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,825 shares of the company’s stock after selling 152 shares during the quarter. Eidelman Virant Capital’s holdings in AbbVie were worth $1,268,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. EagleClaw Capital Managment LLC raised its stake in AbbVie by 3.7% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 70,273 shares of the company’s stock valued at $7,575,000 after acquiring an additional 2,524 shares during the last quarter. MFA Wealth Advisors LLC purchased a new stake in AbbVie during the 3rd quarter valued at approximately $51,000. Summit Trail Advisors LLC purchased a new stake in AbbVie during the 3rd quarter valued at approximately $259,000. Capstone Triton Financial Group LLC raised its stake in AbbVie by 20.6% during the 3rd quarter. Capstone Triton Financial Group LLC now owns 5,682 shares of the company’s stock valued at $617,000 after acquiring an additional 969 shares during the last quarter. Finally, Winning Points Advisors LLC raised its stake in shares of AbbVie by 3.1% during the 3rd quarter. Winning Points Advisors LLC now owns 7,257 shares of the company’s stock worth $783,000 after buying an additional 219 shares in the last quarter. 67.03% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE:ABBV opened at $147.56 on Thursday. The business’s fifty day moving average price is $150.17 and its two-hundred day moving average price is $146.18. The stock has a market cap of $260.75 billion, a PE ratio of 21.17, a price-to-earnings-growth ratio of 4.04 and a beta of 0.83. The company has a debt-to-equity ratio of 3.89, a quick ratio of 0.71 and a current ratio of 0.82. AbbVie Inc. has a one year low of $105.56 and a one year high of $175.91.
ABBV has been the subject of a number of analyst reports. StockNews.com raised AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 8th. Morgan Stanley increased their target price on AbbVie from $142.00 to $192.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 6th. Citigroup increased their target price on AbbVie from $155.00 to $170.00 in a research note on Tuesday, March 1st. BMO Capital Markets increased their target price on AbbVie from $161.00 to $174.00 and gave the stock an “outperform” rating in a research note on Monday, April 25th. Finally, Wells Fargo & Company upped their price target on AbbVie from $165.00 to $200.00 in a report on Monday, May 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $159.75.
In related news, EVP Henry O. Gosebruch sold 83,960 shares of the stock in a transaction on Monday, May 16th. The stock was sold at an average price of $155.00, for a total value of $13,013,800.00. Following the transaction, the executive vice president now directly owns 16,623 shares of the company’s stock, valued at approximately $2,576,565. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Vice Chairman Michael Severino sold 100,000 shares of the stock in a transaction on Friday, May 6th. The stock was sold at an average price of $150.81, for a total value of $15,081,000.00. Following the completion of the transaction, the insider now directly owns 152,103 shares in the company, valued at $22,938,653.43. The disclosure for this sale can be found here. Insiders have sold 463,761 shares of company stock worth $70,609,771 in the last 90 days. Insiders own 0.08% of the company’s stock.
AbbVie Company Profile (Get Rating)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.